A daigou buys consumer goods abroad on behalf of people living in China.
Showing 25 of 2928
Important addition to the company's current European and global IP portfolio.
The company has filed three new provisional patent applications in the US.
The agreement follows a successful, revenue-generating launch of cannaQIX® in Switzerland and Lichtenstein.
The single tranche placement will see new shares issued priced at 3.4 cents.
The trial will test the safety, efficacy and dose tolerance in cancer patients.
Colorectal cancer is the second largest cause of cancer-related deaths in Australia.
The capital raising could potentially be a placement, rights issue or share purchase plan.
The company's shares closed about 17% higher today, at 2.7 cents.
PeriCoach system is now indicated for urinary incontinence, sexual wellness and pelvic organ prolapse.
The medical device company’s major shareholder Crystal Amber Fund Limited has made the commitment.
Revenue from the sale of Xprecia Stride™ Coagulation Analyser test strips was $500,000 in the March quarter of 2018.
The pilot project will assess the ResAppDx, ResApp’s smartphone application for diagnosing acute respiratory disease.
DigiPath's aims to improve reliability with state of the art lab equipment
Overseas Advanced Drug Development expenditure for RECCE® 327 results in extra payment of $861,590.
Shares in the company were halted having last traded at 61 cents.
Regeneus’ Progenza is a stem cell technology platform developed for the treatment of knee osteoarthritis.
Cann is scaling up substantially to compete on the global medicinal cannabis stage.
OncoSil is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer.
Ellex iTrack and Ellex tango™ offer surgeons restorative glaucoma therapy options.
Enabling oncologists to develop better informed and more personalised treatment strategies for patients.
Cynata’s lead product was recently granted Orphan Drug Designation by the US FDA.
The company is developing BTX 1204, a new treatment for eczema.
Corporate health initiatives are focusing on mental health and wellbeing of employees.
The funds raised will be used to complete phase II clinical trial in Duchenne Muscular Dystrophy (DMD) patients.